Welcome to our dedicated page for Bayer A G news (Ticker: BAYZF), a resource for investors and traders seeking the latest updates and insights on Bayer A G stock.
The BAYZF news page on Stock Titan aggregates recent announcements and press releases related to Bayer AG, a global life science company with core competencies in health care and nutrition. Investors and observers can use this feed to follow how Bayer communicates about its pharmaceutical pipeline, radiology developments, crop science launches and broader corporate strategy.
Recent Bayer news has highlighted updates on its Pharmaceuticals Division, including growth plans built around high-value products and a modality-rich pipeline in oncology, cardiology, neurology, immunology and women’s health. Releases describe pivotal approvals, regulatory milestones, and clinical data from programs in areas such as stroke prevention, heart failure, chronic kidney disease, prostate cancer, lung cancer and menopause-related vasomotor symptoms.
The news flow also covers Bayer’s activities in radiology and molecular imaging, such as clinical results for an investigational low-dose MRI contrast agent and the acquisition of investigational PET and SPECT tracers for diagnosing cardiac amyloidosis. In addition, company communications report collaborations in advanced modalities like cell and gene therapy and siRNA-based treatments, as well as progress in rare kidney diseases including Alport Syndrome.
Beyond human health, Bayer’s crop science releases describe new insecticides and seed treatments for crops such as canola and pulses, illustrating its role in agricultural inputs and food production. Together, these updates provide context on how Bayer pursues its stated mission of “Health for all, Hunger for none” across pharmaceuticals, diagnostics and agriculture. For anyone tracking BAYZF, this news page offers a centralized view of the company’s reported clinical milestones, product launches, partnerships and strategic initiatives over time.
Bayer (BAYRY) has initiated a global Phase II trial (NCT07625215) of BAY 3670549, an investigational highly selective GIRK4 inhibitor, in adults with atrial fibrillation (AFib) who require electrical cardioversion.
The randomized, double-blind, placebo-controlled, parallel-group, multi-cohort study will evaluate the drug’s efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics. BAY 3670549 showed a generally favorable safety and tolerability profile in healthy participants in a completed first-in-human, single-ascending-dose Phase I study, which supports further clinical development. Derived from Bayer’s strategic research alliance with the Broad Institute of MIT and Harvard, the compound is being investigated as a novel pharmacologic approach for rapid cardioversion to normal sinus rhythm that could offer an alternative to electrical cardioversion, the current gold standard for AFib.
Bayer (OTC:BAYRY, BAYZF) reported first detailed Phase III REVEAL data for investigational PET radiotracer iodine 124 evuzamitide (AT‑01) in suspected cardiac amyloidosis, presented as a late‑breaker at ESC 2026 and published in JAMA.
The multicenter, open‑label, single‑arm study enrolled 170 U.S. patients with suspected cardiac amyloidosis. According to Bayer, the study met its primary endpoints: majority‑read sensitivity was 94% (95% CI 85–98) and specificity was 86% (95% CI 77–92) for visual PET scan interpretation.
Secondary analyses showed majority‑read sensitivity/specificity of 96%/86% in transthyretin amyloidosis (ATTR) and 95%/86% in light‑chain amyloidosis (AL). Among 170 treated patients, 32.4% experienced at least one treatment‑emergent adverse event and 6.5% had serious events deemed unrelated; only one fatigue case was considered related. No deaths or evuzamitide‑related discontinuations occurred.
I 124 evuzamitide has Breakthrough Therapy and Orphan Drug designations in the U.S. (AL and ATTR) and Orphan status in the EU. The tracer remains investigational and unapproved; Bayer plans to discuss these Phase III results and a potential regulatory submission with the FDA and other health authorities.
Bayer (OTC:BAYRY, BAYZF) will feature 11 oral presentations from its cardiovascular, kidney and secondary stroke prevention programs at the ESC Congress 2026 in Munich, August 28–31, 2026. Highlights include late-breaking Phase III data on KERENDIA (finerenone) in chronic kidney disease (CKD) with and without diabetes, hypertensive nephropathy, and heart failure with LVEF ≥40%.
Bayer will also present full Phase III REVEAL results for investigational PET radiotracer I 124 evuzamitide in suspected cardiac amyloidosis, and a new OCEANIC-STROKE analysis on dual antiplatelet therapy and Factor XIa inhibitor asundexian in secondary stroke prevention, alongside multiple additional finerenone analyses.
Bayer (OTC:BAYRY) received a Notice of Compliance from Health Canada expanding the market authorization of LYNKUET (elinzanetant) to treat moderate to severe vasomotor symptoms (VMS) caused by adjuvant endocrine therapy (AET) related to breast cancer. LYNKUET is now the first approved treatment option in Canada for this specific patient group.
This builds on its July 2025 Canadian authorization for VMS associated with menopause. According to Bayer, the expanded indication is supported by the Phase III OASIS-4 trial in women on AET, and by the broader OASIS program where elinzanetant showed significant VMS frequency reductions versus placebo with a placebo-like safety profile.
One A Day (BAYRY, BAYZF), a Bayer brand, introduced a new formula for its Women's Multi Gummy, now providing 1,000 mcg of Biotin per two-gummy serving. According to One A Day, this delivers 2,833% Daily Value of biotin, compared with 150 mcg in several leading women’s multivitamin gummies.
The gummies also include Vitamins A, C, D, E, B3, B5, B6, B12 and Zinc, formulated without artificial sweeteners, high fructose corn syrup or FD&C color additives. The product is positioned to support hair, skin, nails, bone, heart‡, immune and muscle health*, and is available now at Walmart stores nationwide and online.
Bayer (OTC:BAYRY, BAYZF) supported new Economist Enterprise research on integrating self-care into health systems. The report, “Making self-care work: integrating self-care into health systems”, finds that well-governed, evidence-based self-care with reliable information, affordable access and clear referral pathways can improve health outcomes, expand access and ease pressure on overstretched systems.
The research cites existing evidence estimating about US$179 billion in annual economic benefits from self-care and highlights policy priorities: translating commitments into action, ensuring equitable, trusted support, and strengthening measurement and accountability. Country examples include Germany’s “green prescriptions” and Indonesia’s GERMAS movement.
Bayer (OTC:BAYRY) and Henry Ford Health announced a strategic research partnership to expand patient access to clinical trials across Henry Ford’s integrated care network. Henry Ford Health was selected as one of only four U.S. academic health systems in Bayer’s strategic research network.
The collaboration initially targets cardiovascular and renal disease (including thrombosis, heart failure, stroke, and chronic kidney disease), oncology (advanced cancers and targeted therapies), and women’s health (menopausal symptoms and gynecologic conditions). The partners plan to work jointly across the full clinical trial process, using data and technology to design trials and reduce barriers to participation so patients may access investigational therapies closer to home.
Beyond trials, they intend to cooperate on AI, analytics, electronic health record data use, real-world evidence generation, and training in healthcare data science, with the aim of making research faster, more inclusive, and more accessible.
Sabanto, a provider of autonomous retrofit technology for agriculture, announced an oversubscribed Series B financing led by Leaps by Bayer (BAYRY), with participation from Sustainable Forward Capital, InnoVenture Iowa, Fulcrum Global Capital, DCVC, and Yara. The funding is intended to accelerate commercial adoption of Sabanto’s retrofit autonomy platform for row crop farming.
According to Sabanto, proceeds will support expanded commercialization and dealer networks, increased retrofit kit production and deployment, continued software and autonomy development, enhanced customer support and field operations, and faster adoption in the row crop market, while enabling smaller, autonomous equipment to improve efficiency, labor allocation, and potentially soil health.
Bayer (OTC:BAYRY) formed a strategic clinical trial alliance with University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, its first with an academic medical center. The collaboration targets oncology, cardiovascular, kidney, neurodegenerative disease, cell and gene therapy, women’s health and ophthalmology, aiming to expand trial capacity and patient access to investigational therapies.
Bayer (OTC:BAYRY) announced a collaboration between its One A Day brand and country artist Luke Bryan for limited edition multivitamin gummy bottles.
The One A Day Men & Women’s Multi Gummy bottles, featuring Luke Bryan, are sold exclusively at select Walmart stores nationwide for $9.97 from July through September.